Anavex Life Sciences’ (AVXL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research report report published on Thursday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock.

Separately, EF Hutton Acquisition Co. I raised Anavex Life Sciences to a strong-buy rating in a research report on Monday, July 22nd.

Anavex Life Sciences Stock Down 4.8 %

NASDAQ AVXL traded down $0.31 during trading on Thursday, hitting $6.18. The stock had a trading volume of 211,202 shares, compared to its average volume of 1,323,490. The company has a market capitalization of $524.06 million, a PE ratio of -12.99 and a beta of 0.63. The firm has a 50 day moving average price of $4.77 and a 200 day moving average price of $4.84. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). During the same period last year, the company earned ($0.17) earnings per share. On average, sell-side analysts anticipate that Anavex Life Sciences will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its holdings in shares of Anavex Life Sciences by 32.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,637 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 2,594 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Anavex Life Sciences by 10.0% in the fourth quarter. New York State Common Retirement Fund now owns 29,321 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 2,670 shares during the period. Independent Advisor Alliance increased its holdings in shares of Anavex Life Sciences by 10.4% in the fourth quarter. Independent Advisor Alliance now owns 47,644 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 4,500 shares during the period. Fiduciary Alliance LLC increased its holdings in shares of Anavex Life Sciences by 45.2% in the second quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,000 shares during the period. Finally, Carnegie Capital Asset Management LLC increased its holdings in shares of Anavex Life Sciences by 9.3% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 73,660 shares of the biotechnology company’s stock valued at $686,000 after purchasing an additional 6,250 shares during the period. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.